SG11201805229YA - Means and methods for treating hbv - Google Patents
Means and methods for treating hbvInfo
- Publication number
- SG11201805229YA SG11201805229YA SG11201805229YA SG11201805229YA SG11201805229YA SG 11201805229Y A SG11201805229Y A SG 11201805229YA SG 11201805229Y A SG11201805229Y A SG 11201805229YA SG 11201805229Y A SG11201805229Y A SG 11201805229YA SG 11201805229Y A SG11201805229Y A SG 11201805229YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- munich
- pct
- hbv
- vector
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002255 vaccination Methods 0.000 abstract 6
- 241000700721 Hepatitis B virus Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Photoreceptors In Electrophotography (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Catalysts (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 July 2017 (20.07.2017) WIPO I PCT (10) International Publication Number WO 2017/121791 Al 11111111111111011101111111111101011111011101110111010111111111011111111111110111111 (51) International Patent Classification: C12N 15/86 (2006.01) A61K 39/29 (2006.01) (21) International Application Number: PCT/EP2017/050553 (22) International Filing Date: 12 January 2017 (12.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 92942 12 January 2016 (12.01.2016) LU (71) Applicant: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GE- SUNDHEIT UND UMWELT (GMBH) [DE/DE]; Ingol- stadter LandstraBe 1, 85764 Neuherberg (DE). (72) Inventors: PROTZER, Ulrike; Anzlgutstr. 45, 81735 Mu- nich (DE). BAUER, Tanja; Waldstr. 10, 85570 Otten- hofen (DE). KOSINSKA, Anna; Edlingerstr. 15, 81543 Munich (DE). MUECK-HAEUSL, Martin; Lilienthalstr. 32a, 85579 Munich (DE). (74) Agents: WEINZIERL, Gerhard et al.; Schiweck Weinzi- erl Koch, European Patent Attorneys, Landsberger Strasse 98, 80339 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 171217 / 9 1 Al (54) Title: MEANS AND METHODS FOR TREATING HBV (57) : The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92942 | 2016-01-12 | ||
PCT/EP2017/050553 WO2017121791A1 (en) | 2016-01-12 | 2017-01-12 | Means and methods for treating hbv |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805229YA true SG11201805229YA (en) | 2018-07-30 |
Family
ID=55237880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805229YA SG11201805229YA (en) | 2016-01-12 | 2017-01-12 | Means and methods for treating hbv |
Country Status (21)
Country | Link |
---|---|
US (1) | US10912827B2 (en) |
EP (1) | EP3402888B1 (en) |
JP (1) | JP6743154B2 (en) |
KR (1) | KR20180100228A (en) |
CN (2) | CN116732101A (en) |
AU (1) | AU2017207764B2 (en) |
BR (1) | BR112018013387A2 (en) |
CA (1) | CA3002508A1 (en) |
DK (1) | DK3402888T3 (en) |
ES (1) | ES2834698T3 (en) |
HR (1) | HRP20201873T1 (en) |
HU (1) | HUE052104T2 (en) |
IL (1) | IL260525B (en) |
PL (1) | PL3402888T3 (en) |
PT (1) | PT3402888T (en) |
RS (1) | RS61118B1 (en) |
RU (1) | RU2740802C2 (en) |
SG (1) | SG11201805229YA (en) |
SI (1) | SI3402888T1 (en) |
WO (1) | WO2017121791A1 (en) |
ZA (1) | ZA201802644B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017210181A1 (en) | 2016-05-30 | 2017-12-07 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
KR102672900B1 (en) * | 2016-09-01 | 2024-06-10 | (주)아모레퍼시픽 | COMPOSITION FOR MELANIN-ENHANCING COMPRISING 2,4-DICHLORO-A-(3,4-DIHYDRO-4-OXO-2(1H)-QUINAZOLINYLIDENE)-β-OXO-BENZENEPROPANENITRILE |
JP2020516673A (en) * | 2017-04-18 | 2020-06-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Method of treating a subject having hepatitis B virus (HBV) infection |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
CN110913898B (en) | 2017-04-18 | 2024-04-05 | 阿尔尼拉姆医药品有限公司 | Methods of treating subjects having Hepatitis B Virus (HBV) infection |
WO2018229179A1 (en) * | 2017-06-14 | 2018-12-20 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
GB201721068D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
GB201721069D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
AU2018389786A1 (en) * | 2017-12-19 | 2020-06-18 | Bavarian Nordic A/S | Methods and compositions for inducing an immune response against hepatitis B virus (HBV) |
SG11202100715WA (en) | 2018-08-13 | 2021-02-25 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
SG11202107510SA (en) * | 2019-01-11 | 2021-08-30 | Agency Science Tech & Res | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
WO2020178359A1 (en) * | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
WO2020210628A1 (en) * | 2019-04-10 | 2020-10-15 | Emv Enhance (Hk) Limited | Compositions and methods for improving vaccination of hyporesponsive individuals |
KR20220090497A (en) * | 2019-08-29 | 2022-06-29 | 비르 바이오테크놀로지, 인코포레이티드 | hepatitis B virus vaccine |
CA3161638A1 (en) * | 2019-12-13 | 2021-06-17 | Jun Ge | Pharmaceutical composition and use thereof |
MX2022009962A (en) * | 2020-02-14 | 2022-11-09 | Geovax Inc | Vaccines and uses thereof to induce an immune response to sars-cov2. |
CN116367854A (en) * | 2020-07-08 | 2023-06-30 | 杨森科学爱尔兰无限公司 | RNA replicon vaccine against HBV |
WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
WO2023145755A1 (en) * | 2022-01-25 | 2023-08-03 | 公益財団法人川崎市産業振興財団 | Rna-containing composition for transdermal administration, and method for administering said composition |
WO2023250522A2 (en) * | 2022-06-25 | 2023-12-28 | Administrators Of The Tulane Educational Fund | Vaccine adjuvants and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235288B1 (en) * | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
WO2009056535A2 (en) | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
EP2461826A2 (en) * | 2009-08-07 | 2012-06-13 | Transgene SA | Composition for treating hbv infection |
ES2643389T3 (en) * | 2011-02-12 | 2017-11-22 | Globeimmune, Inc. | Yeast-based therapeutic product for chronic hepatitis B infection |
KR101281098B1 (en) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | Epitope and it's use of Hepatitis B virus surface antigen |
EP3143144A4 (en) * | 2014-05-16 | 2017-12-20 | Yale University | VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION |
-
2017
- 2017-01-12 EP EP17701067.5A patent/EP3402888B1/en active Active
- 2017-01-12 WO PCT/EP2017/050553 patent/WO2017121791A1/en active Application Filing
- 2017-01-12 KR KR1020187023239A patent/KR20180100228A/en unknown
- 2017-01-12 RU RU2018114308A patent/RU2740802C2/en active
- 2017-01-12 BR BR112018013387-6A patent/BR112018013387A2/en unknown
- 2017-01-12 CN CN202310549953.2A patent/CN116732101A/en active Pending
- 2017-01-12 HU HUE17701067A patent/HUE052104T2/en unknown
- 2017-01-12 AU AU2017207764A patent/AU2017207764B2/en active Active
- 2017-01-12 CN CN201780006621.2A patent/CN109154004B/en active Active
- 2017-01-12 RS RS20201424A patent/RS61118B1/en unknown
- 2017-01-12 ES ES17701067T patent/ES2834698T3/en active Active
- 2017-01-12 CA CA3002508A patent/CA3002508A1/en active Pending
- 2017-01-12 DK DK17701067.5T patent/DK3402888T3/en active
- 2017-01-12 PT PT177010675T patent/PT3402888T/en unknown
- 2017-01-12 SG SG11201805229YA patent/SG11201805229YA/en unknown
- 2017-01-12 PL PL17701067T patent/PL3402888T3/en unknown
- 2017-01-12 JP JP2018535373A patent/JP6743154B2/en active Active
- 2017-01-12 US US16/069,268 patent/US10912827B2/en active Active
- 2017-01-12 SI SI201730523T patent/SI3402888T1/en unknown
-
2018
- 2018-04-20 ZA ZA2018/02644A patent/ZA201802644B/en unknown
- 2018-07-10 IL IL260525A patent/IL260525B/en unknown
-
2020
- 2020-11-25 HR HRP20201873TT patent/HRP20201873T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RS61118B1 (en) | 2020-12-31 |
EP3402888A1 (en) | 2018-11-21 |
HUE052104T2 (en) | 2021-04-28 |
CA3002508A1 (en) | 2017-07-20 |
EP3402888B1 (en) | 2020-08-26 |
JP2019505205A (en) | 2019-02-28 |
US10912827B2 (en) | 2021-02-09 |
RU2018114308A3 (en) | 2020-02-13 |
DK3402888T3 (en) | 2020-11-30 |
AU2017207764B2 (en) | 2023-04-27 |
KR20180100228A (en) | 2018-09-07 |
CN109154004B (en) | 2023-06-06 |
BR112018013387A2 (en) | 2019-03-06 |
JP6743154B2 (en) | 2020-08-19 |
SI3402888T1 (en) | 2021-02-26 |
PT3402888T (en) | 2020-12-04 |
RU2740802C2 (en) | 2021-01-21 |
HRP20201873T1 (en) | 2021-01-22 |
CN116732101A (en) | 2023-09-12 |
WO2017121791A1 (en) | 2017-07-20 |
AU2017207764A1 (en) | 2018-05-10 |
ES2834698T3 (en) | 2021-06-18 |
CN109154004A (en) | 2019-01-04 |
RU2018114308A (en) | 2020-02-13 |
ZA201802644B (en) | 2023-07-26 |
PL3402888T3 (en) | 2021-04-19 |
US20190030158A1 (en) | 2019-01-31 |
IL260525B (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201408459VA (en) | Purification of virus like particles | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201809594WA (en) | Nicotine particles and compositions |